Market closedNon-fractionalADR
Adaptimmune Therapeutics/ADAP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Adaptimmune Therapeutics
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
Ticker
ADAP
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Abingdon, United Kingdom
Employees
449
Website
www.adaptimmune.com
ADAP Metrics
BasicAdvanced
$289M
Market cap
-
P/E ratio
-$0.73
EPS
2.33
Beta
-
Dividend rate
Price and volume
Market cap
$289M
Beta
2.33
52-week high
$2.05
52-week low
$0.42
Average daily volume
34
Financial strength
Current ratio
2.814
Management effectiveness
Return on assets (TTM)
-59.85%
Return on equity (TTM)
-301.91%
Return on investment (TTM)
-78.55%
Valuation
Price to revenue (TTM)
15.731
Price to book
11.845
Price to tangible book (TTM)
12.108
Growth
Revenue change (TTM)
-74.21%
Earnings per share change (TTM)
-3.66%
3-year revenue growth
147.88%
What the Analysts think about ADAP
Analyst Ratings
Majority rating from 8 analysts.
ADAP Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$5.6M
2,700.00%
Net income
-$49M
1.25%
Profit margin
-866.07%
-96.38%
ADAP Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.12
-$0.20
-$0.24
-$0.18
-
Expected
-$0.13
-$0.12
-$0.10
-$0.10
-$0.11
Surprise
-9.87%
72.41%
140.00%
83.67%
-
ADAP News
AllArticlesVideos
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
Benzinga·3 weeks ago
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
Newsfile Corp·1 month ago
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Newsfile Corp·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adaptimmune Therapeutics stock?
Adaptimmune Therapeutics (ADAP) has a market cap of $289M as of July 06, 2024.
What is the P/E ratio for Adaptimmune Therapeutics stock?
The price to earnings (P/E) ratio for Adaptimmune Therapeutics (ADAP) stock is 0 as of July 06, 2024.
Does Adaptimmune Therapeutics stock pay dividends?
No, Adaptimmune Therapeutics (ADAP) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Adaptimmune Therapeutics dividend payment date?
Adaptimmune Therapeutics (ADAP) stock does not pay dividends to its shareholders.
What is the beta indicator for Adaptimmune Therapeutics?
Adaptimmune Therapeutics (ADAP) has a beta rating of 2.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Adaptimmune Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.